Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

  title={Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.},
  author={Sarah M. Robertson and Richard T Davey and Jocelyn Voell and Elizabeth Formentini and Raul M. Alfaro and Scott R. Penzak},
  journal={Current medical research and opinion},
  volume={24 2},
OBJECTIVE Animal and in vitro data suggest that Ginkgo biloba extract (GBE) may modulate CYP3A4 activity. As such, GBE may alter the exposure of HIV protease inhibitors metabolized by CYP3A4. It is also possible that GBE could alter protease inhibitor pharmacokinetics (PK) secondary to modulation of P-glycoprotein (P-gp). The primary objective of the study was to evaluate the effect of GBE on the exposure of lopinavir in healthy volunteers administered lopinavir/ritonavir. Secondary objectives… Expand
Effect of Ginkgo Biloba on the Pharmacokinetics of Raltegravir in Healthy Volunteers
The effect of ginkgo biloba extract on the pharmacokinetics of raltegravir in an open-label, randomized, two-period, crossover phase I trial in 18 healthy volunteers was studied, and no serious adverse events were reported. Expand
Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices
This study suggests that GBE slightly decreases the plasma atorvastatin concentrations, but has no meaningful effect on the cholesterol-lowering efficacy of atorVastatin. Expand
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects
  • L-L Dai, L. Fan, +6 authors H. Zhou
  • Medicine
  • Xenobiotica; the fate of foreign compounds in biological systems
  • 2013
GBE consumption decreased simvastatin system exposure, but did not affect simvastsatin acid PK, and it cannot rule out the possibility for a pharmacodynamic interaction between GBE and simVastatin in vivo. Expand
Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers.
Ginkgo biloba extract treatment appears to reduce significantly the t(1/2) and increase the C(max) of hydroxybupropion, and no bupropion dose adjustments appear warranted when the drug is administered orally with G. biloba Extract, due to the lack of significant change observed in AUC for either bupropions or hydroxy bupropions. Expand
Effects of Ginkgo biloba Extract on the Oral Bioavailability of Fluoxetine and Venlafaxine in Rats
GK extract shows no physicochemical interactions with fluoxetine or venlafaxine, and the results showed that GK extract has no significant effects on the bioavailability of fluoxettine and venl Lafaxine. Expand
Effect of Garlic, Gingko, and St. John’s Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study
The aim of this study was to determine the effects of garlic and ginkgo herbal extracts on the pharmacokinetics of the P-glycoprotein (P-gp)/organic anion-transporting polypeptides (Oatps) substrateExpand
Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers
RG has no relevant potential to cause CYP enzyme- or P-glycoprotein-related interactions and no clinically significant drug interactions were observed between RG and CYP and P-gp probe substrates. Expand
and Efavirenz Ginkgo biloba Herbal Interaction between − A Potential Drug
Efavirenz (EFV) is primarily metabolized by cytochrome P450 (CYP) 2B6 and to a lesser extent by CYP3A4. Drugs that significantly inhibit or induce these enzymes would then be expected to increase orExpand
Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P‐glycoprotein (P‐gp) Activity in Healthy Participants
Patients taking P ginseng in combination with CYP3A substrates with narrow therapeutic ranges should be monitored closely for adequate therapeutic response to the substrate medication. Expand
Pharmacokinetic drug interactions involving Ginkgo biloba
  • M. Unger
  • Biology, Medicine
  • Drug metabolism reviews
  • 2013
Regarding pharmacokinetic herb–drug interactions, the intake of the standardized GLE, EGb 761, together with synthetic drugs appears to be safe as long as daily doses up to 240 mg are consumed, but if this applies to other extracts prepared according to the European Pharmacopoeia remains uncertain. Expand